- Home
- ELEV vs ALXO Comparison
ELEV vs ALXO Comparison
Compare ELEV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- ALXO
- Stock Information
- Founded
- ELEV 2019
- ALXO 2015
- Country
- ELEV United States
- ALXO United States
- Employees
- ELEV N/A
- ALXO N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- ALXO Health Care
- Exchange
- ELEV Nasdaq
- ALXO Nasdaq
- Market Cap
- ELEV 22.6M
- ALXO 24.0M
- IPO Year
- ELEV 2021
- ALXO 2020
- Fundamental
- Price
- ELEV $0.38
- ALXO $0.48
- Analyst Decision
- ELEV Hold
- ALXO Strong Buy
- Analyst Count
- ELEV 6
- ALXO 6
- Target Price
- ELEV $1.77
- ALXO $3.30
- AVG Volume (30 Days)
- ELEV 938.5K
- ALXO 600.5K
- Earning Date
- ELEV 08-05-2025
- ALXO 08-07-2025
- Dividend Yield
- ELEV N/A
- ALXO N/A
- EPS Growth
- ELEV N/A
- ALXO N/A
- EPS
- ELEV N/A
- ALXO N/A
- Revenue
- ELEV N/A
- ALXO N/A
- Revenue This Year
- ELEV N/A
- ALXO N/A
- Revenue Next Year
- ELEV N/A
- ALXO N/A
- P/E Ratio
- ELEV N/A
- ALXO N/A
- Revenue Growth
- ELEV N/A
- ALXO N/A
- 52 Week Low
- ELEV $0.22
- ALXO $0.40
- 52 Week High
- ELEV $3.28
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- ELEV 54.73
- ALXO 50.61
- Support Level
- ELEV $0.36
- ALXO $0.44
- Resistance Level
- ELEV $0.38
- ALXO $0.53
- Average True Range (ATR)
- ELEV 0.01
- ALXO 0.04
- MACD
- ELEV -0.00
- ALXO 0.01
- Stochastic Oscillator
- ELEV 53.93
- ALXO 61.67
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.